• Very few studies have investigated the burden of PSS. A previous health economic study in PSS by Lundstrom et al. (2010) 2 compared all direct costs (both stroke and non-stroke related) during one year after the first ever stroke for patients with and without spasticity. The study found that the frequency of spasticity was 18% and there was a four-fold increase in direct costs for PSS.
Objective
• The aim of this study was to describe the burden of PSS in terms of healthcare resource utilisation and quantify the difference in costs between patients developing PSS and those who do not.
Methods
• This was a retrospective observational study using primary care data from The Health Improvement Network (THIN).
• Patients were included in the study if they had a stroke event, as identified by a list of Read codes 3 between 1 January 2007 and 31 December 2011. Patients who died on the date of the stroke were excluded.
Cases and Controls Selection
• Included patients with a stoke were further classified into potential cases and controls ( Figure 1 ).
• Potential cases were patients with a PSS event in the eligibility period (1 January 2007 -31 December 2011). PSS was initially identified using Read codes only, but the proportion of patients identified was ~1%, substantially lower than that reported in previous publications (30%-60%), suggesting spasticity could be under recorded in the United Kingdom (UK) primary care setting.
• Machine learning methodologies were applied in order to identify potentially undiagnosed PSS patients and to prevent selection bias when comparing patients with PSS and patients with stroke but without PSS.
• Predicted PSS events were also included as potential cases.
• Potential controls were all patients with no PSS event in the study period. 
Conclusions
• The study showed that the costs in the 12 months after stroke for patients who develop PSS are twice that of patients without PSS.
• Although costs were higher for all the areas measured, the main driver of costs was hospitalisation.
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Study Periods
• Index date for each of the groups was defined as the date of stroke occurrence:
-Cases: the stroke event prior to the first ever PSS event -Controls: every stroke event was included and the date of stroke was set as the index date
• The baseline period was defined as index date and the 12 months prior.
• Patients were followed up for 12 months post-stroke.
Matching of Cases and Controls
• To control for potential confounding, the group of cases were matched to at least one control stroke event without PSS.
• Nearest neighbour algorithm matching was performed using the following variables: age at stroke, gender, number of strokes prior to index event, socioeconomic status and comorbidity as measured by the Charlson Comorbidity Index indicator at index date.
• Controls could be matched to more than one case if that was the closest match. Each case was matched to at least one control to determine the effect of spasticity on healthcare costs.
• Stroke events without complete data on the matching variables were excluded (4.3% of cases and 3.7% of controls).
Study Outcomes
• Direct healthcare resources, as captured in the primary care records, during the 12 months after index date included GP visits, nurse visits, hospitalisations, referrals to specialists and referrals to the pathology department for blood tests.
• Resources were costed at 2014 rates using a bottom-up approach. 
Strengths and Limitations
• This study used real-world data from multiple healthcare practices in the UK, with a broader representativeness of the population than single-hospital studies.
• Cases and controls were matched to remove other potential confounding factors driving the differences in costs.
• The severity of the stroke would have been an important factor in understanding the costs attributable to spasticity. However, this information was not available in the data and could not be controlled for in the study.
• Generic unit costs were applied to hospitalisations as more detailed information about the hospitalisation was not available.
• The total average costs per patient in the 12 months post-stroke were £1,269.80 (standard deviation [SD] 771.89) for PSS cases and £635.19 (SD 272.75) for matched controls.
• A similar proportion of over half of the costs were related to GP visits for both groups (Figure 3 ).
• The proportion of hospitalisation costs for cases was twice that of controls.
• On average, in the 12 months after suffering a stroke, healthcare resource costs were £634.60 higher for patients with PSS than those who did not develop PSS.
• All potential cases were matched to at least one control and, on average, each case was matched to 12 controls (median = 10; interquartile range [IQR]: 1-57).
• The final matched cohorts consisted of 2,951 cases matched to 37,753 nonunique controls.
• Balance on key characteristics after matching was assessed and considered satisfactory for analyses (Table 2) .
Healthcare Resources
• Healthcare resource utilisation in patients with PSS was high, with 98.95% visiting the GP at least once and a median of 12 visits the first year after stroke (IQR: 7-21); 55.95% visited the nurse in the 12 months post-stroke ( Figure 2 ).
• Of secondary care, 76.45% was referred to the specialist at least once (median 2; IQR: 1-4) and 33.41% were hospitalised. Abbreviations: PSS, post-stroke spasticity
Results
• The study included 31,835 stroke events, which were classified as 3,082 patients with PSS (403 diagnosed; 2,679 predicted) and 28,753 patients without PSS.
• Stroke events occurred for around half of the study subjects at the age of 75 years old or older (potential cases: 48.8%; potential controls: 53.0%).
• Gender distribution and socioeconomic status were quite evenly distributed (Table 1) . 
